Skip to content
drillr.ai
Sign up

GCTK

Glucotrack, Inc.

NASDAQ · Healthcare · Medical - Instruments & Supplies · IL

$2.47
+3.78%
Ask drillr

  • Sep 18, 2026, 21:12 UTC

    Paul V. Goode resigned as a director of Glucotrack, Inc., effective September 14, 2026.

  • Sep 14, 2026, 20:17 UTC

    Glucotrack, Inc. amended its common warrants so that holders cannot exercise them until the company obtains stockholder approval for the issuance of all shares underlying the warrants under Nasdaq Listing Rule 5635(d).

  • Sep 11, 2026, 21:22 UTC

    Glucotrack, Inc. engaged Dawson James Securities, Inc. as placement agent under a Placement Agency Agreement with a 7% cash fee and warrants to purchase 148,668 shares.

  • Sep 11, 2026, 12:00 UTC

    Glucotrack announced an $11.5 million convertible note financing, including new capital and note rollover, to support strategic growth.

    Source:

  • Sep 9, 2026, 21:04 UTC

    Glucotrack, Inc. and other settling parties signed a Settlement and Release Agreement with Alto Opportunity Master Fund, SPC, obligating them to pay Alto an initial $2.0 million, an additional $2.0 million via a convertible promissory note, and up to $125,000 in legal fees.

  • Aug 10, 2026, 00:00 UTC

    Glucotrack, Inc. amended its 2026 equity line of credit common stock purchase agreement with White Lion Capital, LLC, setting the issuance of 2,505,513 Commitment Shares and adding a true-up payment mechanism, in connection with a $1,000,000 commitment fee.

  • Aug 5, 2026, 12:30 UTC

    Glucotrack announced approximately $5.5 million in financing, including a $2.0 million equity offering priced at $0.75 per unit and a $3.5 million convertible debt investment from institutional investors.

    Source:

  • Jul 31, 2026, 12:00 UTC

    Glucotrack, through its subsidiary Lōkahi Therapeutics, announced the continued expansion of its ai² Futures Lab, which in its first year identified over 45 therapeutic opportunities on a budget of about $33,000 and advanced five into active discussions.

    Source:

  • Jul 27, 2026, 00:00 UTC

    Glucotrack, Inc. signed an exchange agreement on July 22, 2026, to exchange a $900,000 partitioned promissory note for shares of its common stock, subject to approval by its bridge investors.

  • Jul 17, 2026, 17:20 UTC

    E.F. Hutton & Co. served as exclusive financial advisor on the strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics.

    Source:

  • Jul 17, 2026, 17:20 UTC

    E.F. Hutton & Co. served as exclusive placement agent for a convertible note financing of approximately $5.7 million to support the combined company's post-closing growth.

    Source:

  • Jul 17, 2026, 12:05 UTC

    Glucotrack, Inc. completed a bridge financing to support its strategic growth objectives following its business combination with Lōkahi Therapeutics.

    Source:

  • Jul 14, 2026, 21:40 UTC

    Glucotrack and Lōkahi Therapeutics completed a strategic business combination, establishing a Lōkahi-controlled public platform.

    Source: